Glucocorticoids* ; Osteoblasts*

Granulomatous hypophysitis is an extremely rare condition, with no established definitive treatment. An elderly Asian woman was diagnosed to have recurrent granulomatous hypophysitis 5 years after transsphenoidal surgery. No other intervention was done post-operatively. Since another surgery was not advisable due to the high probability of recurrence, she was started on a trial of oral glucocorticoids. After 3 months of steroid therapy, complete resolution of symptoms and sellar mass were achieved.
Autoimmune Hypophysitis ; Glucocorticoids

GC is wonderful drug to prevent and control bronchial asthma. Methods: 1026 inpatients with asthma presented at the Department of Allergy and Clinical Immunology were included in this study. Cross - sectional surveys and retrospective studies. Objectives: Study on situation of using GC of asthmatic patients. Describe adverse drug reactions of glucocorticoid to asthmatic in - patients at the Department of Allergy and Clinical Immunology. Results: All of 1026 patients used Gc. Prednisolon, solu - medrol, depersolon and pulmicort were most used medications. There were 295 asthmatic patients have side effects (28.75%) with 24 types of symptom, 15 diseases and syndromes are resulted: Cushing syndrome, gastric ulcer, diabetes, hypertension, ponosis, retarded development... Almost systemic organs of the patients were influenced negatively by Gc. It has relationship among the way to use, the time in used GC and adverse drug reactions of GC. Conclusions: GC caused many adverse drug reactions to asthmatic patients.
Asthma ; Status Asthmaticus ; Patients ; Glucocorticoids

Epidermal keratinocytes are important sources of a wide variety of cytokines that include the endothelin-1 (ET-1). Glucocorticoids have been shown to inhibit the production of several cytokines. However, their effect on ET-1 synthesis by keratinocytes is still unknown. It has been reported that ultraviolet B (UVB) irradiation stimulates both the synthesis and release of ET-1 and it was observed that ET-1 secretion by HaCat cells increased with increasing UVB exposure. In this study, the effects of glucocorticoid on ET-1 production were evaluated using cultured HaCat keratinocytes. The results showed that dexamethasone suppressed basal re-lease of ET-1. In addition, it strongly inhibited the UVB-mediated augmentation of ET-1 production. Furthermore, lincomycin slightly enhanced the inhibitory effect of dexamethasone on ET-1 synthesis.
Cytokines ; Dexamethasone* ; Endothelin-1 ; Glucocorticoids ; Keratinocytes* ; Lincomycin

The innate immune system and its complex interplay with the adaptive immune system are increasingly being recognized as important factors in the pathogenesis of chronic rhinosinusitis (CRS). Adaptive immune components, including resident and inflammatory cells, and their associated mediators, have been the subject of most research in CRS. For this reason, theories of CRS pathogenesis have involved the concept that inflammation, rather than infection, is the dominant etiologic factor in CRS. Therefore, glucocorticoids are increasingly used to treat CRS. This review will outline our current knowledge of action mode of glucocorticoids in CRS.
Cytokines ; Glucocorticoids ; Immune System ; Inflammation ; Receptors, Glucocorticoid

No abstract available.
Bone Density* ; Child* ; Glucocorticoids* ; Humans ; Nephrotic Syndrome*

Retrospective study on 1026 patients with asthma at Bach Mai Hospital from 1 January 1998 to 31 January 2002. Among them, 69.4% were 21 to 50 years old, with no different in sex. Hospitalized rate was highest in annual November. Glucocorticoid was used in all these patients with common kinds as solu-medrol: 76.2%; prednisolone: 67.7%; depersolone: 44.3% và Pulmicort: 7.6%. Rate of complication related to glucocorticoids was 28.7%. There were 24 types of symptom, including high blood glucose (11.5%), hypokaliemia (9.45%), hypertension (3.45%), gastric ulcer (2.83%), Cushing syndrome (2.53%). 7 systems damaged were endocrine (27.54%), musculoskeletal (4.28%), skin and mucous membrane (3.19%), gastrointestinal (4.96%), cardiovascular (3.7%), nervous and sense organs. There were 10 kinds of diseases and syndroms related to glucocorticoid use: hypertension, gastric ulcer, Cushing syndrome, diabetes, ponosis, retarded development, urticaria, anapphylactic shock, cataract, metal disorders, secondary bacterial contamination
Asthma ; Glucocorticoids/adverse effects ; Pharmaceutical Preparations

OBJECTIVETo assess the efficacy and safety of hyaluronate sodium (HS) for internal derangement of temporomandibular joint by means of systematic review on relevant randomized controlled trials.

METHODSAfter identifing the study question of the efficacy and safety of HS for internal derangement of temporomandibular joint, Medline, Cochrane Controlled Trials Register, EMBASE, OPEN SIGLE and CBM were searched electronically till October 3rd 2010. Hand-searching covering 19 dental journals in Chinese were also performed. Risk of bias assessment, with Cochrane Collaboration's tool, and data extraction of included studies were conducted by two reviewers in duplicate. Meta analysis was done with Revman 5.0.23 and the quality of evidence was evaluated by GRADE.

RESULTS10 randomized controlled trials met the eligibility criteria and were included. All these studies had unclear risk of bias. When compared with negative control, HS showed a significant advantage on maximal mouth opening in short and long-term (P < 0.05), and clinical overall assessment in short-term (P < 0.05), but its effect on pain control and long-term effect on clinical overall assessment had no extra benefit (P > 0.05). Additionally, when compared with glucocorticoids, the participants who received HS injection would get a better clinical overall assessment in short-term and less adverse drug reactions (P < 0.05), but presented a similar temporomandibular joint pain relief and maximal mouth opening (P > 0.05).

CONCLUSIONTo a certain extent, HS had good efficacy and better safety than controls when treating internal derangement of temporomandibular joint. However, as the quality of some included studies were limited, more randomized controlled trials are needed to reinforce the conclusion.

Glucocorticoids ; therapeutic use ; Humans ; Pemphigus ; therapy

Humans ; Glucocorticoids/therapeutic use* ; Cochlear Implantation